318 related articles for article (PubMed ID: 26216630)
21. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.
Hamilton DH; Huang B; Fernando RI; Tsang KY; Palena C
Cancer Res; 2014 May; 74(9):2510-9. PubMed ID: 24626094
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and immunological targeting of tumor mesenchymalization.
David JM; Dominguez C; Palena C
Pharmacol Ther; 2017 Feb; 170():212-225. PubMed ID: 27916651
[TBL] [Abstract][Full Text] [Related]
24. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.
Palena C; Fernando RI; Litzinger MT; Hamilton DH; Huang B; Schlom J
Exp Biol Med (Maywood); 2011 May; 236(5):537-45. PubMed ID: 21427233
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Du R; Wu S; Lv X; Fang H; Wu S; Kang J
J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
[TBL] [Abstract][Full Text] [Related]
26. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Expression of the Epithelial-Mesenchymal Transition-Related Factor Brachyury in Intrathoracic Lymphatic Spread of Non-Small Cell Lung Cancer.
Shimamatsu S; Okamoto T; Haro A; Kitahara H; Kohno M; Morodomi Y; Tagawa T; Okano S; Oda Y; Maehara Y
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):1012-1020. PubMed ID: 27600618
[TBL] [Abstract][Full Text] [Related]
28. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
29. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.
David JM; Hamilton DH; Palena C
Oncoimmunology; 2016 Apr; 5(4):e1117738. PubMed ID: 27141403
[TBL] [Abstract][Full Text] [Related]
30. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
31. Role of T-box genes in cancer, epithelial-mesenchymal transition, and cancer stem cells.
Niu G; Hao J; Sheng S; Wen F
J Cell Biochem; 2022 Feb; 123(2):215-230. PubMed ID: 34897787
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.
Palena C; Roselli M; Litzinger MT; Ferroni P; Costarelli L; Spila A; Cavaliere F; Huang B; Fernando RI; Hamilton DH; Jochems C; Tsang KY; Cheng Q; Lyerly HK; Schlom J; Guadagni F
J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24815864
[TBL] [Abstract][Full Text] [Related]
33. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.
Huang B; Cohen JR; Fernando RI; Hamilton DH; Litzinger MT; Hodge JW; Palena C
Cell Death Dis; 2013 Jun; 4(6):e682. PubMed ID: 23788039
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
35. Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.
Chockley PJ; Keshamouni VG
J Immunol; 2016 Aug; 197(3):691-8. PubMed ID: 27431984
[TBL] [Abstract][Full Text] [Related]
36. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.
Huang Y; Hong W; Wei X
J Hematol Oncol; 2022 Sep; 15(1):129. PubMed ID: 36076302
[TBL] [Abstract][Full Text] [Related]
37. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.
Ricciardi M; Zanotto M; Malpeli G; Bassi G; Perbellini O; Chilosi M; Bifari F; Krampera M
Br J Cancer; 2015 Mar; 112(6):1067-75. PubMed ID: 25668006
[TBL] [Abstract][Full Text] [Related]
38. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
[TBL] [Abstract][Full Text] [Related]
39. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
Garg M
Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
[TBL] [Abstract][Full Text] [Related]
40. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.
Xu K; Liu B; Liu Y
Mol Med Rep; 2015 Jul; 12(1):995-1001. PubMed ID: 25683840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
